Finalist for Collaborate to Innovate Awards

RNS Number : 1682I
Haydale Graphene Industries PLC
01 December 2022
 
 

REACH

 

For immediate release

01 December 2022

 

 

Haydale Graphene Industries plc

 

('Haydale' or the 'Group')

 

Haydale Finalist for The Engineer's Collaborate to Innovate Awards for MicroRNA Sensor

 

Haydale (AIM: HAYD), the global technology solutions company, is delighted to announce that it has been shortlisted for The Engineer's Collaborate to Innovate Awards (C2I) for its work with the Wales Kidney Research Unit ("WKRU") at Cardiff University on a microRNA sensor for kidney transplant patients.

 

The collaborative team including Haydale, WKRU, Cardiff University Systems Immunity Research Institute, Cardiff University School of Medicine, Cardiff University School of Chemistry, Cardiff and Vale University Health Board and University Hospital of Wales are one of six finalists in the Healthcare and Medical Category forThe Engineer's seventh annual C2I Awards.

 

Already a winner of the Kidney Research UK MedTech Competition, theurinary electrochemical microRNA sensor has the potential to replace slower and more costly PCR-based methods for the rapid detection of problems with newly transplanted kidneys. The sensor uses Haydale's biomedical functionalised graphene ink to accelerate detection without the need for an invasive biopsy.

 

This nomination will support the commercial progress that Haydale is making with its biosensor inks, which have been focused on diabetes monitoring and management. It is anticipated that this will be expanded to wider diagnostics as the technology is adopted.

 

Keith Broadbent, Haydale's CEO, said he was delighted the team's hard work had been recognised, commenting:

 

"This is further recognition of our work in healthcare. Our collaboration has helped to accelerate the provision of cutting-edge technological solutions to improve people's life experience. Using functionalised graphene reduces sensor production time and variability and accelerates translation to improve patient outcomes."

 

Dr Tim Bowen, Reader in Matrix and Molecular Biology at Wales Kidney Research Unit, added:

 

"The team are delighted to be finalists for the C2I awards.Transplants are life-changing, but when they fail the consequences can be devastating. This urinary electrochemical microRNA sensor technology could help identify problems earlier, leading to more timely clinical interventions."

 

The very best in UK collaborations and innovations in engineering will come together in London on Thursday 23 February 2023 for the C2I winners' party.

- Ends -

For further information:

Haydale Graphene Industries plc

Keith Broadbent, CEO    Tel: +44 (0) 1269 842946

Sarah Thomas, Marketing Manager                                                                        Tel: +44 (0) 1269 507026

 

finnCap (Nominated Adviser & Broker)

Julian Blunt / Edward Whiley, Corporate Finance                                                  Tel: +44 (0) 20 7220 0500

Andrew Burdis, ECM

 

Notes to Editors

 

Haydale is a global technologies and materials group that facilitates the integration of graphene and other nanomaterials into the next generation of commercial technologies and industrial materials. With expertise in graphene, silicon carbide and other nanomaterials, Haydale can deliver improvements in electrical, thermal, and mechanical properties, as well as toughness through its state-of-the-art functionalisation. Haydale has granted patents for its technologies in Europe, USA, Australia, Japan, and China and operates from five sites in the UK, USA, and the Far East.

 

For more information please visit: www.haydale.com 

 

LinkedIn: Haydale-ltd

Twitter: @haydalegraphene 

 

About Reach announcements 

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not a Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFDDFASEESEIF
UK 100

Latest directors dealings